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Abstract 
Epigenetic modifications, such as DNA methylation (DNAm), can help explain how early 
adversities can engender long-term vulnerability for mental health problems. At present, there 
is preliminary evidence to support the possibility of epigenetic mediation: environmental 
factors are reported to influence offspring DNAm, which in turn, associate with child and 
adolescent psychopathology. However, all analyses have been correlational in nature and, as 
these studies have focused on children and adolescents, DNAm has been based on peripheral 
tissue (cord blood, whole blood, buccal cells). Therefore, the extent to which DNAm could 
represent a causal mechanism (e.g. a surrogate of central nervous system function) or a 
biomarker (i.e. an indicator of the pathological process leading to disease) is unclear. This 
short report has two main components. First, two studies are summarised, one a candidate 
gene study and the other an epigenome-wide association study, in which DNAm was reported 
to (partially) mediate the link between adversity and child development. Second, there is a 
discussion of (i) the “tissue issue”, (ii) maximizing the interpretability of candidate gene and 
epigenome-wide approaches, and (iii) the need for examining DNAm as a potential 
biomarker for mental health. It is argued that advances within these three areas will make 
clearer the role of DNA methylation in the link between adversity and child and adolescent 
mental health.  
Keywords: DNA methylation; Epigenetics; Developmental Psychopathology; Childhood; 
Adolescence; Adversity; Mediator; Biomarker  
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Introduction 
DNA methylation (DNAm) – an epigenetic process that can regulate gene expression – has 
emerged as a potential mechanism through which the genome can capture the effects of early 
adversity and propagate their influence [1]. The ideas of ‘capturing’ and ‘propagating’ 
summarize a mediational hypothesis: that early adversity can have long-term mental health 
effects (at least partially) via changes in DNAm. However, at present, very few existing 
studies have adopted longitudinal designs capable of testing mediation (i.e. adversity  
DNAm  mental health) – hence, published ‘mediational’ studies are rare [see 2]. Moreover, 
as these studies have focused on living children and adolescents, they have examined DNAm 
from peripheral tissues (e.g. cord blood, whole blood, saliva), but arguably brain tissue is 
more relevant for mental health. As a result, it is not clear if DNAm is a causal mechanism in 
the aetiology of mental health problems (Figure 1a), or a biomarker, in this case, a 
quantitative index of environmental adversity that may be independent of disease 
aetiology (Figure 1b). Herein, two recent DNAm mediation studies are reviewed, followed 
by a discussion of three key areas that could help clarify the role of DNA methylation in the 
link between adversity and mental health. 
Epigenetics and DNA Methylation 
 Prior to reviewing the mediation research, epigenetics and DNAm will be (briefly) 
defined. Epigenetic mechanisms influence dynamic changes in gene transcription 
independent of the genomic DNA sequence, primarily via modifications to DNA, histone 
proteins, and chromatin structure [3]. One of the most extensively researched epigenetic 
mechanisms is DNAm, which refers to the addition of a methyl group, primarily in the 
context of cytosine-guanine (CpG) dinucleotides [3]. In the human genome, CpG sites often 
cluster in CpG-islands, which themselves tend to be embedded in promoter regions of genes. 
Methylated CpG islands impede transcription factors from accessing the DNA sequence. 
Increased methylation in these regions is typically associated with inhibition of gene 
transcription (i.e. gene silencing) and chromatin compaction. Importantly, because epigenetic 
processes have been shown to respond to both genetic [4] and environmental [5] influence, 
they represent a potential mechanism that can help explain the biology of gene-environmental 
interplay and disease susceptibility across the lifespan [6].  
DNA methylation mediation studies 
The ‘promise’ of a mediational framework is that – if adversity-related DNAm is a 
causal link in the aetiology of a mental health problem – then reversing epigenetic marks 
might help in remission of these problems. Although causality has yet to be established and 
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reduced power is an ongoing concern, research has nevertheless demonstrated that DNAm 
may act as a ‘mediator’ in the link between adversity and child outcomes, and hence offer a 
potential target for intervention [see 5]. There is good evidence in animal and human studies 
that prenatal stress can have long-term effects on the child, such as affecting 
neurodevelopment. Here, vulnerability for psychiatric disorders could – in part – be due to 
increased exposure to cortisol and its impact on foetal brain development [7, 8]. In the first 
study of its kind, Monk et al. [9] examined placental DNA methylation as a potential pathway 
in the link between pregnant women’s (n = 61) distress and offspring aberrant development 
(in utero). They reported higher perceived maternal stress in the second trimester (24-27 
gestational weeks) associated with higher methylation of HSD11B2, which is an important 
placental barrier gene that that inactivates cortisol (a correlate of psychological stress).  
Higher DNA methylation of HSD11B2, in turn, associated with a lower score on an index of 
foetal neurodevelopment, the assessment of which took place in the third trimester (34-37 
weeks). The authors stated that increased DNA methylation of HSD11B2 could lead to the 
downregulation of the placental barrier enzyme, hence a pathway to elevated in utero 
exposure to stress-related cortisol.  
In another mediation study, a ‘hypothesis free’ genome-wide strategy was taken. This 
approach allows for the discovery of novel biological correlates (as opposed to testing a priori 
defined candidate genes), which can aid in the development of more holistic etiologic 
knowledge. Here, Cecil et al. [10], using the epidemiological birth cohort, the Avon 
Longitudinal Study of parents and Children, examined a subset of youth (n = 244) who were 
oversampled for early onset conduct problems (i.e. before age 10; lying, fighting, stealing). 
The researchers tested epigenome-wide, prospective associations between DNA methylation 
(birth, age 7) and substance use in adolescence (tobacco, alcohol and cannabis use; age 14–
18). It was reported that at birth (but not at age 7), epigenetic variation across a tightly 
interconnected genetic network (n = 65 epigenome-wide significant loci) associated with 
higher levels of substance use. Key annotated genes included PACSIN1, NEUROD4 and 
NTRK2, implicated in neurodevelopmental processes. In addition, prenatal maternal tobacco 
smoking prospectively associated with adolescent substance use via the epigenetic variation 
of these 65 loci (i.e. a poly-epigenetic risk score). Of interest, several of the 65 loci were 
associated with known methylation quantitative trait loci [see 4], which means that the levels 
of DNA methylation are likely under a degree of genetic influence. In fact, the loci that 
associated with methylation quantitative trait loci (‘under genetic influence’) showed higher 
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continuity between birth and age 7 than the loci that were not associated with methylation 
quantitative trait loci (‘not under genetic influence’).  
Discussion 
Although the above studies show that DNAm can act as a mediator between risk 
exposure and child psychopathology, it is important to note that they are correlational in 
nature (non-causal). Below, three key areas are discussed that can help clarify the role of 
DNAm in the link between adversity and mental health. We note that other areas not covered 
here are also important, such as genetic influence, cellular heterogeneity, temporal variability, 
replication and functional characterisation of DNAm [see 2, 11].  
1. The issue of peripheral tissue as a surrogate for central nervous system (CNS) function 
Although the brain may be of ultimate interest, for studies on living persons, 
available options include collecting accessible peripheral tissues such as saliva, buccal 
epithelial cells or blood. A major debate has centred on the utility of peripheral tissues for 
mental illnesses that primarily manifest in the brain [12]. Indeed, studies on the correlation 
between peripheral and CNS show mixed patterns: while a majority of CpGs do not show 
intra-individual associated, a minority do [13] –  especially those under genetic influence [14, 
15].  
A strategy worth considering is to target mental health problems that have 
mechanistic underpinnings in other tissues, including blood [12]. Blood is a primary tissue 
for research focused on immune response and peripheral inflammation [16, 17]. Indeed, a 
wide-range of psychiatric disorders have been associated with peripheral inflammation and 
altered immune response [18]. Moreover, there is good evidence from animal studies, and 
increasing evidence in humans, that peripheral inflammatory markers can affect brain areas 
implicated in certain psychiatric disorders [19, 20]. Consequently, adversity-related immune 
processes and DNAm may be well measured in blood samples. 
2. Candidate gene vs genome-wide strategies 
Early DNAm studies, before the advent of genome-wide techniques, focused on 
specific candidate genes that were selected a priori, due to known functional relevance for 
certain mental illnesses. This strategy is best with highly targeted research questions (as in 
Monk [11] investigating placental barrier genes). However, given the discussion directly 
above, a complimentary approach is to not only focus on candidate genes involved in 
inflammatory response, but also on whole systems that functionally interrelate with immune 
response and brain development, such as the hypothalamic pituitary adrenal axis [20]. The 
suggestion here is to prioritize candidate genes or systems that have plausible pathways to the 
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CNS. Of note, several online databases catalogue known associations of DNAm between 
peripheral and post-mortem brain samples [14, 15]. 
In recent years, genome-wide DNAm studies have become more popular, due to 
their increased affordability and data content [11]. The Cecil et al. study reviewed above may 
be an exemplar, as the top loci formed a network that was plausibly linked with 
neurodevelopmental risk for substance use. However, not all genome-wide studies have 
clear-cut results. Given that intra-individual variation in a majority of the peripheral-based 
CpGs in genome-wide arrays tend not to co-vary with those in the brain [14, 15], one may 
question is if it is worth examining these arrays in their entirety. For researchers interested in 
maximizing CpGs likely to associate with brain-based mental illnesses, an a priori set of 
CpGs (e.g. a ‘systems approach’) could be isolated from the array data, which could still span 
thousands of loci [see 21]. Again, the suggestion is to prioritize CpGs within biological 
systems that are believed to associate with CNS function. An alternative approach could be to 
prioritize CpGs with underlying methylation quantitative trait loci (mQTLs), which have 
been validated in both peripheral and CNS tissues [14]. 
3. Establishing DNAm as a biomarker 
Blood-based DNAm studies have shown promising associations with respect to both 
environmental adversity and mental illness [12]. One promising avenue is to establish DNAm 
as a biomarker for mental illness. For biomarkers to be useful, they must be cost effective, 
drawn from accessible tissue and predictive of future risk [22]. One advantage of a biomarker 
is that it does not have to be mechanistic (i.e. CNS surrogate) [Figure 1, panel b; see also 22]. 
Indeed, blood-based biomarkers have been used for diagnostics, predictive risk, disease 
monitoring and/or treatment response in cancer, cardiovascular and infectious disease [23, 
24]. Although biomarkers for brain-based disorders (Alzheimer’s disease, depression) have 
proven more difficult to establish [24], using a genome-wide approach based on blood tissues 
across 13 population-based cohorts, Liu, Marioni [25] reported that a set of 144 CpGs 
discriminated drinkers from non-drinkers (area under the curve: >0.90). It was suggested that 
a blood-based DNAm diagnostic test could be developed to validate self-report data, in a 
forensic setting or as a screening test. However, as the Liu, Marioni [25] study was cross-
sectional, the authors noted that they could not rule out reverse causality (i.e. DNAm may be 
caused by alcohol intake); therefore, additional research is needed to determine if the set of 
144 CpGs could be predictive of problematic levels of future alcohol usage.  
The recent interest in epigenetics, from a developmental psychopathology 
perspective, stems from the potential of DNA methylation – whether as a causal mechanism 
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or as a biomarker – to index both exposure to adversity and vulnerability for mental health 
problems [2]. Toward this end, there has been substantial activity the ‘epigenetics’ of 
adversity-related disorders, such as post-traumatic stress disorder [26] and borderline 
personality disorder [27]. Of interest, DNA methylation in genes that underlie stress 
response, neurotransmitter activity and immune regulation have been identified [27]. These 
preliminary findings may provide a useful framework for more in-depth investigations of 
both the pathogenesis and clinical responsiveness of these disorders. For example, if 
adversity affects peripheral DNA methylation in a gene, which, in turn, reliably increases 
vulnerability for borderline personality disorder (i.e. high predictive specificity), then an 
efficacious intervention may also show change in both DNA methylation of the candidate 
gene and mental health symptoms for responders versus non-responders (i.e. a potential 
causal mechanism in symptoms). Although this area of research is in early stages, certain 
small scale (proof of concept) interventions have reported joint change in DNA methylation 
of candidate genes and symptoms of mental health problems including borderline personality 
[28] and anxiety [29]. Large scale randomised controlled trials are needed to increase 
scientific rigor and to establish causality. Application of epigenome-wide methods [e.g. see 
30, 31] may be especially useful for the discovery of novel biological systems that may be 
mechanisms – or biomarkers – of treatment response and symptom change. 
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Figure 1. The potential of DNA methylation (DNAm) within developmental 
psychopathology studies. A. DNAm as a causal biological mechanism, associating with 
environmental adversity and subsequent vulnerability for mental health problems. B. DNAm 
as an adversity-related biomarker of subsequent mental health problems. Note. Other 
epigenetic markers, such as histone modification, can be used in the same way as DNAm. 
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